Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 9/20 | 0.48 |
| ▸ | HTR2A | P28223 | 9/20 | 0.48 |
| ▸ | DRD2 | P14416 | 8/20 | 0.48 |
| ▸ | HRH1 | P35367 | 3/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.38 |
| ▸ | FNTA | P49354 | 1/20 | 0.36 |
| ▸ | FNTB | P49356 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25596768 | 0.85 | HTR1A (0.45) | HTR1AHTR2ADRD2HRH1CHRM2 | |
| SCHEMBL2632787 | 0.80 | MTNR1A (0.43) | HTR1AHTR2ADRD2HRH1CHRM2 | |
| SCHEMBL3399553 | 0.77 | HTR1A (0.48) | HTR1AHTR2ADRD2ADAM17 | |
| SCHEMBL19699124 | 0.74 | HTR1A (0.47) | HTR1AHTR2ADRD2HRH1CHRM2 | |
| SCHEMBL9252869 | 0.73 | ADAM17 (0.45) | HTR1AHTR2ADRD2ADAM17DPP8 | |
| SCHEMBL31484091 | 0.71 | DRD2 (0.39) | HTR1AHTR2ADRD2HRH1CHRM2 | |
| SCHEMBL20690890 | 0.71 | DPP8 (0.41) | DRD2DPP8DPP9 | |
| SCHEMBL803066 | 0.71 | HTR1A (0.40) | HTR1AHTR2ADRD2HRH1CHRM2 | |
| SCHEMBL11947839 | 0.70 | HTR1A (0.46) | HTR1AHTR2ADRD2ADAM17 | |
| SCHEMBL24729037 | 0.69 | ALDH1A1 (0.47) | DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | MAPT, HTT, PSEN1 | HTR1A 4035/4885HTR2A 4191/4885DRD2 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.